Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: The curacao extrapyramidal syndromes study XII

Journal of Clinical Psychiatry

Volumn 78, Issue 3, 2017, Pages e279-e285

  Mentzel, Charlotte L ^a,b   Bakker, P Roberto ^a,b   Os, Jim Van ^a,c   Drukker, Marjan ^a   Matroos, Glenn E ^d   Hoek, Hans W ^e,f,h   Tijssen, Marina A J ^g   Harten, Peter N Van ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Psychiatric Centre GGZ Centraal   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Psychiatric Centre GGz Curaçao   (Netherlands)

^e PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^f Departments of Psychiatry   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIRST GENERATION ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-III-R; FEMALE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PARKINSONISM; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; UNIFIED PARKINSON DISEASE RATING SCALE; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DRUG EFFECTS; DRUG SUBSTITUTION; MENTAL DISORDERS; MIDDLE AGED; NETHERLANDS ANTILLES; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; PROTOCOL COMPLIANCE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DOPAMINE AGENTS; DRUG SUBSTITUTION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NETHERLANDS ANTILLES; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 85017009715     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m11049     Document Type: Article

References (34)

1. Bakker PR, de Groot IW, van Os J, et al. Longstay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6(10):e25588. PubMed doi:10.1371/journal.pone.0258
2. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151-156. PubMed doi:10.1097/YCO.0b013e3282f53132
3. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs. 2012;26(6):491-508. PubMed doi:10.2165/1632020-0-0
4. Leucht S, Corves C, Arbter D, et al. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet. 2009;373(9657):31-41. PubMed doi:10.1016/S0140-6736(08)61764-X
5. Tenback DE, van Harten PN, Slooff CJ, et al; SOHO Study Group. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry. 2007;48(5):436-440. PubMed doi:10.1016/j.compsych.207.05.03
6. van Harten PN, Bakker PR, Mentzel CL, et al. Movement disorders and psychosis, a complex marriage. Front Psychiatry. 2015;5:190. PubMed doi:10.389/fpsyt.2014.0190
7. Bakker PR, de Groot IW, van Os J, et al. Predicting the incidence of antipsychoticinduced movement disorders in long-stay patients: a prospective study. Epidemiol Psychiatr Sci. 2013;22(4):375-379. PubMed doi:10.1017/S2045796013019X
8. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33-43. PubMed doi:10.1016/j.schres.205.07.034
9. Van Harten PN. Movement disorders associated with neuroleptics: the Curaçao Extrapyramidal Syndromes Study [dissertation]. Utrecht, The Netherlands: Utrecht University; 1998.
10. Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148, viii. PubMed doi:10.1016/j.ncl.2010.10.02
11. Bhidayasiri R, Fahn S, Weiner WJ, et al; American Academy of Neurology. Evidencebased guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-469. PubMed doi:10.1212/WNL.0b013e31829d86b6
12. Psychosis and Schizophrenia in Adults: Treatment and Management. NICE UK Web site. https://www.nice.org.uk/guidance/cg178. 2014.
13. van Alphen C, Ammeraal M, Blanke C, et al. Multidisciplinaire richtlijn schizofrenie. Utrecht, the Netherlands: Nederlandse Vereniging voor Psychiatrie; 2012.
14. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087. PubMed doi:10.101/archpsyc.63.10.1079
15. Owens DC. A Guide to the Extrapyramidal Side- Effects of Antipsychotic Drugs. 2nd edition. New York, NY: Cambridge University Press; 2014. doi:10.1017/CBO97813914912
16. van Harten PN, Matroos GE, Hoek HW, et al. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curaçao Extrapyramidal Syndromes Study, I. Schizophr Res. 1996;19(2-3):195-203. PubMed doi:10.1016/0920-964(95)096-8
17. Ruggeri M, Leese M, Thornicroft G, et al. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry. 2000;177:149-155. PubMed doi:10.192/bjp.17.2.149
18. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173(6):353-357. PubMed doi:10.1097/05053-1985060-05
19. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164.
20. Collaborating Centre for Drugs Statistics Methodology. WHO Web site. http://www. whocc.no/atcddd/. Cited 2013 June.
21. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-1486. PubMed doi:10.17/0912706292126
22. Stata Statistical Software: Release 12 [computer program]. College Station, TX: StataCorp LP; 2011.
23. Tenback DE, van Harten PN, Slooff CJ, et al; SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66(9):1130-1133. PubMed doi:10.408/JCP.v6n0907
24. Emsley R, Turner HJ, Schronen J, et al. A singleblind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696-701. PubMed doi:10.408/JCP.v65n0516
25. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry. 1982;39(7):803-816. PubMed doi:10.101/archpsyc.1982.04290703708
26. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. PubMed doi:10.107/s131-013-02-5
27. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487. PubMed doi:10.101/archpsyc.1982.04290408014
28. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-542. PubMed doi:10.1517/1474038.2012.683523
29. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry. 2003;18(5):432-440. PubMed doi:10.102/gps.862
30. Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69-73. PubMed doi:10.1097/jcp.0b013e318160864f
31. Suzuki T, Uchida H, Tanaka KF, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol. 2003;18(6):323-329. PubMed doi:10.1097/04850-20310-03
32. Bachmann S, Degen C, Geider FJ, et al. Neurological soft signs in the clinical course of schizophrenia: results of a meta-analysis. Front Psychiatry. 2014;5:185.
33. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. PubMed doi:10.1016/S0140-6736(13)6073-3
34. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull. 2009;35(3):549-562. PubMedoi:10.1093/schbul/sbp06